Latest Biotech News

Roche announced a new global Phase 3 trial for Elevidys (delandistrogene moxeparvovec), seeking a path toward European approval after a negative European Medicines Agency review. The study is...

UCB agreed to buy Neurona for up to $1.2 billion, adding seizure cell therapy ambitions to its predominantly small-molecule neurology portfolio. UCB said the acquisition is intended to diversify...

FDA’s Office of Prescription Drug Promotion (OPDP) enforcement is intensifying, reshaping what pharma can say and show in promotional materials. A compliance analysis described a rapid expansion...

Takara Bio and Resistomap strengthened their partnership to develop high-throughput antimicrobial resistance (AMR) surveillance products from environmental samples. The SmartChip Biosecurity...

Delta-Fly Pharma said it is pursuing an NDA path for radgocitabine (DFP-10917) after a Phase 3 AML trial missed its primary endpoint. The company plans to discuss with the FDA using earlier-stage...

Revolution Medicines’ daraxonrasib won a major Phase 3 survival signal in metastatic pancreatic cancer, driving deal and pipeline attention around its RAS-targeting approach. The company reported...

BioSpace tallies showed biopharma layoffs slowed year over year in Q1 2026, but total affected employees rose. The reported jump was driven largely by Viatris planning to cut up to 10% of its...

Transformative Biotech said it has developed extraction-free PCR chemistry for point-of-care testing, removing the bottleneck of nucleic acid extraction from sample workflows. The company’s...

Kailera Therapeutics launched one of the biggest biotech IPOs in years, pricing an upsized offering that raised $625 million to fund clinical development of an obesity-focused pipeline licensed...

Multiple companies moved through public-market milestones and strengthened investor access to capital, highlighting how underwriting appetite is focusing on clinical readiness and platform...

Roche moved to restart Europe-focused evidence for Duchenne muscular dystrophy gene therapy Elevidys by announcing a new global phase III trial. The study is designed to generate additional...

Eli Lilly reported positive cardiovascular safety results for its oral obesity and diabetes medicine Foundayo (orforglipron), meeting the main goal of a heart safety trial in a phase III program...

Revolution Medicines reported a survival advantage for its pan-RAS drug daraxonrasib in a global phase III study in metastatic pancreatic ductal adenocarcinoma. Patients treated with the daily...

UCB agreed to acquire Neurona in a deal valued at up to $1.2 billion, aiming to broaden its epilepsy portfolio beyond small molecules. UCB said the acquisition helps diversify into a potentially...

Neomorph secured a $100 million Series B round to advance its oral molecular glue degrader NEO-811 through clinical development and support broader pipeline progress. The company plans continued...

Storm Therapeutics raised $56 million in a Series C to fund phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3-driven methylation pathways in selected sarcoma subtypes. The...

Foundation Medicine, a Roche subsidiary, agreed to buy Saga Diagnostics for up to $595 million, adding the company’s tumor-informed MRD platform Pathlight to Foundation’s test portfolio. The deal...

Biopharma continued to slow layoffs in the first quarter of 2026 compared with the prior year, but headcount reductions still climbed in aggregate due to large-company cuts. According to BioSpace...

UCB will buy Neurona in a deal valued at up to $1.2 billion, positioning the Belgian pharma to broaden beyond its small-molecule epilepsy portfolio with a potentially one-off cell therapy. The...

Revolution Medicines reported a landmark survival benefit for its investigational RAS-targeting drug daraxonrasib (RMC-6236) in a global Phase 3 trial in metastatic pancreatic ductal...